Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C19H24N2O |
| Molecular Weight | 296.4067 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CC(C(N)=O)(C1=CC=CC=C1)C2=CC=CC=C2)N(C)C
InChI
InChIKey=NARHAGIVSFTMIG-UHFFFAOYSA-N
InChI=1S/C19H24N2O/c1-15(21(2)3)14-19(18(20)22,16-10-6-4-7-11-16)17-12-8-5-9-13-17/h4-13,15H,14H2,1-3H3,(H2,20,22)
| Molecular Formula | C19H24N2O |
| Molecular Weight | 296.4067 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Aminopentamide is a potent antispasmodic agent. As a cholinergic blocking agent for smooth muscle, its action is similar to atropine. Aminopentamide hydrogen sulfate is marketed under the brand name Centrine indicated in the treatment of acute abdominal visceral spasm, pylorospasm or hypertrophic gastritis and associated nausea, vomiting and/or diarrhea of the dogs and cats. Centrine effectively reduces the tone and amplitude of colonic contractions to a greater degree and for a more extended period than does atropine. Centrine effects a reduction in gastric secretion, a decrease in gastric acidity and a marked decrease in gastric motility. Aminopentamide is a nonselective muscarinic cholinergic .
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Centrine Approved UseCentrine is indicated in the treatment of acute abdominal visceral spasm, pylorospasm or hypertrophic gastritis and associated nausea, vomiting and/or diarrhea. Launch Date1970 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The pharmacological activity of DL-alpha, alpha-diphenyl, gamma-dimethylaminovaleramide (centrine). | 1954 Jan |
|
| Some aspects of the pharmacology and clinical application of a parasympatholytic agent, aminopentamide. | 1956 Sep 1 |
|
| [Broncholytic effect of a new synthetic drugs: aminopentamide]. | 1957 Jun |
Patents
Sample Use Guides
Dogs and cats: Administer by subcutaneous or intramuscular injection every 8 to 12 hours as follows: For animals weighing up to 10 pounds (lbs): 0.1 mg; For animals weighing 11 to 20 lbs: 0.2 mg; For animals weighing 21 to 50 lbs: 0.3 mg; For animals weighing 51 to 100 lbs: 0.4 mg; For animals weighing over 100 lbs: 0.5 mg. Dosage may be gradually increased up to a maximum of five times the suggested dosage. Following parenteral use, dosage may be continued by oral administration of tablets.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:27:24 GMT 2023
by
admin
on
Sat Dec 16 10:27:24 GMT 2023
|
| Record UNII |
HI3DVH9WMI
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
22565
Created by
admin on Sat Dec 16 10:27:24 GMT 2023 , Edited by admin on Sat Dec 16 10:27:24 GMT 2023
|
PRIMARY | |||
|
5985-88-6
Created by
admin on Sat Dec 16 10:27:24 GMT 2023 , Edited by admin on Sat Dec 16 10:27:24 GMT 2023
|
PRIMARY | |||
|
HI3DVH9WMI
Created by
admin on Sat Dec 16 10:27:24 GMT 2023 , Edited by admin on Sat Dec 16 10:27:24 GMT 2023
|
PRIMARY |